Evidence map›Paper›PMID 31453917›Full record

ArticleJournal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society2020

Outcomes After Transcervical Thymectomy for Ocular Myasthenia Gravis: A Retrospective Cohort Study With Inverse Probability Weighting.

Ali G Hamedani, Maxwell Pistilli, Sunil Singhal, Kenneth S Shindler, Robert A Avery, Madhura A Tamhankar, Grant T Liu

Open access · greenAbstract read
In one paragraph

Article in Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Thymectomy and Risk of Generalization in Patients with Ocular Myasthenia Gravis: A Multicenter Retrospective Cohort Study.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021
    Article
  6. Controversies in Ocular Myasthenia Gravis.Frontiers in neurology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Ali G HamedaniDepartment of Neurology (AGH, KSS, RAA, MAT, and GTL), University of Pennsylvania, Philadelphia, Pennsylvania; Center for Preventive Ophthalmology and Biostatistics (MP), Department of Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Surgery, Division of Thoracic Surgery (SS), University of Pennsylvania, Philadelphia, Pennsylvania; and Department of Ophthalmology (KSS, RAA, MAT, and GTL), Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania.
Maxwell Pistilli
Sunil Singhal
Kenneth S Shindler
Robert A Avery
Madhura A Tamhankar
Grant T Liu
University of Pennsylvania · US

Funding

Scientific TransparencyP30EY001583 · NEI · UNIVERSITY OF PENNSYLVANIA · PI CLAIRE H MITCHELL · 1985 to 2026
$19.5M
Neurologic Clinical Epidemiology Training ProgramT32NS061779 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI Andrea Lauren Christman Schneider, Allison Willis · 2008 to 2026
$4.6M
NEI NIH HHS P30 EY001583NINDS NIH HHS T32 NS061779
6 · The paper itself

Abstract

backgroundThe benefit of thymectomy in reducing requirement for corticosteroids, symptom severity, need for immunosuppression, and hospitalization rates in patients with seropositive generalized myasthenia has recently been established. It is unclear whether this benefit applies to patients with myasthenia and purely ocular manifestations (ocular myasthenia gravis [OMG]).

methodsWe conducted a retrospective single-center cohort study of patients with OMG. Patients were included if their diagnosis was confirmed by acetylcholine receptor or muscle-specific kinase antibodies, abnormal electrophysiology, or a positive edrophonium test and at least 1 year of clinical follow-up. At each visit, the presence and severity of ocular and generalized symptoms was ascertained using a 4-point scale. Prednisone dose, steroid-sparing agent use, and need for intravenous immunoglobulin or plasmapheresis were recorded. The effect of thymectomy on time-weighted prednisone dose and symptom severity score was assessed using linear regression models. To adjust for nonrandomization of thymectomy, we used inverse probability weighting using a propensity score model derived from the prethymectomy observation period for thymectomy patients and a 6-month lead-in period for nonthymectomy patients that incorporated age, sex, acetylcholine receptor antibody seropositivity, disease severity (as defined by both symptom severity and treatment requirement), and treating physician preferences.

resultsEighty-two patients (30 with thymectomy and 52 nonthymectomy) were included. In unadjusted analyses, time-weighted daily prednisone dose was 2.9 mg higher with thymectomy compared with nonthymectomy (95% CI: 0.2-5.7), but after inverse probability weighting, this was no longer statistically significant (difference = 1.7 mg, 95% CI: -0.8 to 4.2). There was no statistically significant difference in symptom severity score (adjusted difference = 0.35, 95% CI: -0.02 to 0.72) or risk of generalization (P = 0.22).

conclusionsIn this retrospective study that used statistical techniques to account for nonrandomization, no significant differences in prednisone dose or symptom severity after thymectomy in ocular myasthenia were demonstrated.

Indexed as

AdultAgedAutoantibodiesCohort StudiesFemaleHumansMaleMiddle AgedMyasthenia GravisReceptors, CholinergicRetrospective StudiesThymectomyTreatment OutcomeAutoantibodiesReceptors, Cholinergic

Identifiers

PMID31453917
PMCPMC7012703
OpenAlexW2970870615

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.